Prognostic significance of cyclin D1 expression in colorectal cancer: A meta-analysis of observational studies

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Li, Yang ^a   Wei, Jun ^a   Xu, Chuanhui ^b   Zhao, Zhongxin ^a   You, Tiangeng ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLIN D1; CCND1 PROTEIN, HUMAN;

AGE DISTRIBUTION; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CELL CYCLE PROGRESSION; CHEMORADIOTHERAPY; COLORECTAL CANCER; DISEASE FREE SURVIVAL; HUMAN; METASTASIS; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR INVASION; COLORECTAL TUMOR; META ANALYSIS; METABOLISM; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PUBLISHING;

COLORECTAL NEOPLASMS; CYCLIN D1; DISEASE-FREE SURVIVAL; HUMANS; OBSERVATIONAL STUDY AS TOPIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PUBLICATION BIAS;

EID: 84899653770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094508     Document Type: Article

References (47)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, et al. (2005) Colorectal cancer. Lancet 365: 153-165. (Pubitemid 40091806)
2. Xu AG, Yu ZJ, Jiang B, Wang XY, Zhong XH, et al. (2010) Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World journal of gastroenterology: WJG 16: 960.
3. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
4. Hunter T, Pines J (1994) Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582. (Pubitemid 24363801)
5. Nevins JR (1992) E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429.
6. Besson A, Dowdy SF, Roberts JM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159-169. (Pubitemid 351189186)
7. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, et al. (1996) Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110: 669-674. (Pubitemid 26071834)
8. Palmqvist R, Stenling R, Oberg A, Landberg G (1998) Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer 34: 1575-1581. (Pubitemid 28446340)
9. Maeda K, Chung YS, Kang SM, Ogawa M, Onoda N, et al. (1997) Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74: 310-315. (Pubitemid 27321801)
10. Bahnassy AA, Zekri AR, El-Houssini S, El-Shehaby AM, Mahmoud MR, et al. (2004) Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol 4: 22.
11. Holland TA, Elder J, McCloud JM, Hall C, Deakin M, et al. (2001) Subcellular localisation of cyclin D1 protein in colorectal tumours is associated with p21(WAF1/CIP1) expression and correlates with patient survival. Int J Cancer 95: 302-306. (Pubitemid 32847040)
12. Bukholm IK, Nesland JM (2000) Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch 436: 224-228. (Pubitemid 30168680)
13. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, et al. (2001) Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 44: 523-533. (Pubitemid 32336426)
14. Pasz-Walczak G, Kordek R, Faflik M (2001) P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathol Res Pract 197: 683-689. (Pubitemid 33019174)
15. McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, et al. (2002) Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 196: 386-393. (Pubitemid 34262849)
16. Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, et al. (2005) Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J Clin Pathol 58: 509-514. (Pubitemid 40646872)
17. Hilska M, Collan YU,Kossi J, Hirsimaki P, et al. (2005) The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum 48: 2197-2208. (Pubitemid 43074439)
18. Ogino S, Nosho K, Irahara N, Kure S, Shima K, et al. (2009) A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 15: 4431-4438.
19. Lyall MS, Dundas SR, Curran S, Murray GI (2006) Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 12: 1184-1191. (Pubitemid 43342507)
20. Wang Y, Xie C, Li Q, Xu K, Wang E (2013) Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol 34: 2169-2174.
21. Von Stockmar-Von Wangenheim CA, Monig SP, Schneider PM, Landsberg S, Drebber U, et al. (2008) p16, cyclin D1 and Rb expression in colorectal carcinomas: Correlations with clinico-pathological parameters and prognosis. Mol Med Rep 1: 27-32.
22. Tsai HL, Yeh YS, Chang YT, Yang IP, Lin CH, et al. (2013) Co-existence of cyclin D1 and vascular endothelial growth factor protein expression is a poor prognostic factor for UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol 107: 148-154.
23. Theocharis S, Giaginis C, Parasi A, Margeli A, Kakisis J, et al. (2007) Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. Dig Dis Sci 52: 2305-2311. (Pubitemid 47246534)
24. Mao Y, Li Z, Lou C, Zhang Y (2011) Expression of phosphorylated Stat5 predicts expression of cyclin D1 and correlates with poor prognosis of colonic adenocarcinoma. Int J Colorectal Dis 26: 29-35.
25. Balcerczak E, Pasz-Walczak G, Kumor P, Panczyk M, Kordek R, et al. (2005) Cyclin D1 protein and CCND1 gene expression in colorectal cancer. Eur J Surg Oncol 31: 721-726. (Pubitemid 41194648)
26. Sobin LH, Gospodarowicz MK, Wittekind C (2010) TNM classification of malignant tumours, 7th edition.
27. Wells G, Shea B, O'Connell D, Peterson P, Welch V, et al. (2011) The Newcatsle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Ottawa: Ottawa Hospital Research Institute.
28. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
29. Yusuf S, Peto R, Lewis J, et al. (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335-371. (Pubitemid 15107153)
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
31. Wang A, Yoshimi N, Suzui M, Yamauchi A, Tarao M, et al. (1996) Different expression patterns of cyclins A, D1 and E in human colorectal cancer. J Cancer Res Clin Oncol 122: 122-126. (Pubitemid 26037056)
32. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, et al. (2010) BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 102: 1762-1768.
33. Moore HG, Shia J, Klimstra DS, Ruo L, Mazumdar M, et al. (2004) Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts longterm outcome. Ann Surg Oncol 11: 955-961. (Pubitemid 40486660)
34. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, et al. (2009) Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 24: 875-884.
35. Belt EJ, Brosens RP, Delis-van Diemen PM, Bril H, Tijssen M, et al. (2012) Cell cycle proteins predict recurrence in stage II and III colon cancer. Ann Surg Oncol 19 Suppl 3: S682-692.
36. Zhao J, Li L, Wei S, Gao Y, Chen Y, et al. (2012) Clinicopathological and prognostic role of cyclin D1 in esophageal squamous cell carcinoma: a metaanalysis. Diseases of the Esophagus 25: 520-526.
37. Xu XL, Chen SZ, Chen W, Zheng WH, Xia XH, et al. (2013) The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a metaanalysis. Breast Cancer Res Treat 139: 329-339.
38. Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, et al. (2001) Correlation of beta-catenin and cyclin D1 expression in colon cancers. Oncology 61: 226-233. (Pubitemid 34701538)
39. Sutter T, Doi S, Carnevale KA, Arber N, Weinstein IB (1997) Expression of cyclins D1 and E in human colon adenocarcinomas. J Med 28: 285-309. (Pubitemid 28168519)
40. Kristt D, Turner I, Koren R, Ramadan E, Gal R (2000) Overexpression of cyclin D1 mRNA in colorectal carcinomas and relationship to clinicopathological features: an in situ hybridization analysis. Pathol Oncol Res 6: 65-70. (Pubitemid 30262782)
41. Bartkova J, Lukas J, Strauss M, Bartek J (1994) The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer 58: 568-573. (Pubitemid 24268101)
42. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, et al. (1996) Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 73: 294-300. (Pubitemid 26047506)
43. Lukas J, Bartkova J, Welcker M, Petersen OW, Peters G, et al. (1995) Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10: 2125-2134.
44. McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, et al. (2000) Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer 88: 77-81.
45. Hall PA, Meek D, Lane DP (1996) p53-integrating the complexity. J Pathol 180: 1-5.
46. Oda K, Okabayashi T, Kataoka M, Takeda A, Shibuya Y, et al. (1999) Evaluation of cyclin D1 mRNA expression in gastric and colorectal cancers. Res Commun Mol Pathol Pharmacol 105: 237-252. (Pubitemid 30636788)
47. Jang KY, Kim YN, Bae JS, Chung MJ, Moon WS et al. (2012) Expression of cyclin D1 is associated withb-catenin expression and correlates with good prognosis in colorectal adenocarcinoma. Translational Oncology 5: 370-378.